Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Date of Graduation
12-12-2025
Semester of Graduation
Fall
Course Instructor
Kristy Liskey
Abstract
Objective: To compare symptom management of atopic dermatitis between injectable monoclonal antibodies and an oral Janus kinase 1 (JAK1) inhibitor. Design: Literature review. Methods: Searches were done in PubMed and CINAHL using the following terms: abrocitinib, Cibinqo, dupilumab, Dupixent, and atopic dermatitis. Filters included: randomized controlled trials, clinical trials, and scholarly journal. Results: Three studies met all criteria including Bieber et al, Reich et al, and Huang et al. Conclusion: Oral JAK1 inhibitor abrocitinib has been shown to have similar efficacy in symptom management of moderate-to-severe atopic dermatitis compared to monoclonal antibody dupilumab and should be considered when prescribing treatment.
Recommended Citation
1. NIAMS. Atopic dermatitis. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Published 2022. https://www.niams.nih.gov/health-topics/atopic-dermatitis 2. Silverberg J, Howe W. Atopic dermatitis (eczema): pathogenesis, clinical manifestations, and diagnosis. UpToDate. Published 2024. Accessed September 2024. https://www.uptodate.com/contents/atopic-dermatitis-eczema-pathogenesis-clinical-mani festations-and-diagnosis?search=atopic%20dermatitis&source=search result&selected _ T itle=4%7E150&usage _ type=default&display_ rank=4#H2 3. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy and Asthma Proceedings. 2019;40(2):84-92. doi:https://doi.org/10.2500/aap.2019.40.4202 4. Deeks ED, Duggan S. Abrocitinib: first approval. Drugs. 2021;81(18):2149-2157. doi:https://doi.org/10.1007/s40265-021-01638-3 5. Description and Appraisal of Outcome Measures. Canadian Agency for Drugs and Technologies in Health, 1 June 2020. www.ncbi.nlm.nih.gov/books/NBK565237/. 6. Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. The New England Journal of Medicine. 2021;384(12):1101-1112. doi:https://doi.org/10.1056/NEJMoa2019380 7. Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273-282.doi:https://doi.org/10.1016/s0140-6736(22)01199-0 8. Huang D, Lu J, Tan F. Improvement of pruritus and efficacy in the early stage of therapy with upadacitinib, abrocitinib, or dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: Prospective, cohort, observational study. Dermatitis. 2024;35(1):77-83. doi:10.1089/derm.2023.0132 9. Eczema (atopic dermatitis) | NIH: National Institute of Allergy and Infectious Diseases. Nih.gov. Published 2017. https://www.niaid.nih.gov/diseases-conditions/eczema-atopic-dermatitis
Included in
Other Chemicals and Drugs Commons, Skin and Connective Tissue Diseases Commons, Therapeutics Commons
